Amboy Street Ventures

Thank you Fortune and Emma Hinchliffe for highlighting Amboy Street Ventures’ latest research: The ‘Ghost Market’ Report. Our work unveils a $360B gap in women's health and sexual health—a vast opportunity for outsized financial returns recognized by few. This market represents 40 unmet needs in menopause, sexual health, aging, menstruation, contraception, LGBTQ health, maternal health, and fertility that demand innovation and investment. Despite the opportunity, only .5% of VC funding goes to women's health, while 30% goes to healthcare at large. This report acts as a blueprint to investing in the women's health ‘ghost market’, providing market sizes, investable innovation, and a call to action for more capital. Fortune exclusive: https://lnkd.in/gn9FEXQh. Ghost Market report: https://lnkd.in/ged7xbjv Featured Companies Contraline, Natural Cycles°, Pozitivf Fertility, Conceivable Life Sciences, Maven Clinic, Progeny, Sunfish, Granata Bio, Gameto, Béa Fertility, Proov, Nodal Surrogacy, Attn: Grace, Jude, Rippl, Hello Heart, AOA Dx, FOLX Health, Mae, Origin, Millie, Pomelo Care, Seven Starling, Dionysus Digital Health, Mirvie, Alloy Women's Health, Respin Health, Midi Health, Joylux, Inc, Gesynta Pharma AB, Aunt Flow, Eli Health, Testmate Health, Dame Products, Evvy, Hey Jane, Rosy Wellness... and more!

We are incredibly proud of our portfolio company Evvy for launching the first vaginal microbiome-based fertility insights test! Priyanka Jain, Laine Bruzek, Pita Navarro and the rest of the Evvy team continue to push the boundaries of innovation in women's health, achieving scientific feats that drive our industry forward. We remain steadfast supporters and customers of Evvy!

Amboy Street Ventures is excited to announce its latest investment in Millie - a midwifery-led, hybrid maternity clinic providing in-person and virtual care. In the US, Maternal healthcare is in dire need of improvement. Millie is exemplary in their mission to improve access and outcomes, enabling women, regardless of insurance coverage, to receive the same high-quality, high-touch care. Participating in Millie's $12M Series A alongside TMV and Foreground Capital, Pivotal Ventures, Ingeborg Investments, March of Dimes, Mother Ventures, Joyance Partners, BBG Ventures, Chai Ventures, and Coyote Ventures was a no-brainer! We are ecstatic to be accompanying Anu Sharma and the Millie Team on this journey.

Gesynta Pharma AB, one of our most recent investments, was featured in Forbes for their successful $27M fundraise, fueling their groundbreaking work in endometriosis treatment. Endometriosis affects 1 in 10 women, yet remains one of the most underserved and underfunded areas in healthcare despite a massive, growing market demand for better treatments. Gesynta’s innovative approach has the potential to transform care for millions, and we’re proud to support them as they work to close critical gaps in women’s health. You can find the article below!

Our Founding Partner, Carli Sapir Sapir , is thrilled to be sharing her insights at the Women’s Venture Capital Summit 2025! She’ll be speaking on "Crossing the Finish Line: The Strategies Needed to Raise a Fund in '25" alongside Liza Benson from Moderne Ventures , Casey Caruso from Topology Ventures and Sara Thomas Deshpande from Maven Ventures moderated by Morgan (Webber) Holzaepfel from @adam street partners. Can't make it in person? Join virtually with the link below from 2:50PM- 3:30PM PST https://lnkd.in/gCT3PHsX

Amboy Street's Portfolio Company Evvy is hiring! They are on the lookout for passionate, innovative individuals to join their mission of redefining women’s health. If you're ready to make an impact, check out the roles we’re currently hiring for: 🔹 Head of BD Partnerships- https://lnkd.in/g74wRNR7 🔹 Product Manager- https://lnkd.in/ggRvzkAZ 🔹 Software Engineer- https://lnkd.in/g2ZRKEzp 🔹 Data Analyst- https://lnkd.in/gyKJnded 💡 Know someone who’d be a great fit? Tag them or share this post!

Amboy Street Ventures is thrilled to announce its latest investment in Gesynta Pharma, a biotech company developing a novel non-hormonal drug candidate for the treatment of endometriosis. Endometriosis affects about 10% of women and girls of reproductive age globally. This is equivalent to around 190 million people. Yet there are few solutions and little innovation in the care journey for these patients. We are proud to be supporting Patric Stenberg and the Gesynta Pharma team as they pioneer the advancement of non-hormonal endometriosis care.

The J.P. Morgan Healthcare Conference was fantastic this year! A heartfelt thank you to everyone who joined us at our Women's Health Happy Hour and to our incredible sponsors, Cake and Justworks, for making the event possible. We're deeply grateful to all who hosted us, True Ventures, Capital F, Evvy, KPMG, McKinsey & Company, Foreground Capital, Organon, and continue to drive progress in women's health, expanding the conversation and inspiring innovation.

Amboy Street Ventures is committed to improving fertility care through strategic investments in companies like Granata Bio. We are happy to share our participation in their $15M Series A+ round alongside CooperSurgical and Gedeon Richter Pharma GmbH

🌟 Join Us for the JPM Amboy Street Women’s Health Happy Hour! 🌟 📆 Date: January 14, 2025 🕒 Time: 6-8PM 📍 Location: SF (details upon RSVP) We have limited space so RSVP here: https://lnkd.in/ge7TaMBU We look forward to having a drink with you to celebrate innovation in women’s health. #WomensHealth #JPMHealthcare #AmboyStreetVentures